Agios Pharmaceuticals GAAP EPS of -$7.12 misses by $0.06, revenue of $54.03M beats by $7.91M
Source: SeekingAlpha
2026-02-12 06:33:29 ET
More on Agios Pharmaceuticals
- Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
- Agios Pharmaceuticals Q4 2025 Earnings Preview
- FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults
Read the full article on Seeking Alpha
For further details see:
Agios Pharmaceuticals GAAP EPS of -$7.12 misses by $0.06, revenue of $54.03M beats by $7.91M
Agios Pharmaceuticals Inc.
NASDAQ: AGIO
AGIO Trading
2.16% G/L:
$28.61 Last:
125,350 Volume:
$28.51 Open:
AGIO Latest News
March 10, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
March 03, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
March 02, 2026 07:00:00 am
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
February 23, 2026 10:57:17 am
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
AGIO Stock Data
$1,577,971,753
55,806,318
0.06%
106
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
